Alaunos Therapeutics Inc
TCRT
NASDAQ
Biotechnology
$1.93
USD
-0.06 (-3.02%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $4.86M
Volume 11.1K
Revenue
$3,000
TTM
-70.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-4.11M
TTM
-1.0%
YoY
Operating Cash Flow
$-3.13M
TTM
+18.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | +100.0% | -100.0% | — | -25.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 0.7 | 0.9 | 0.7 | 0.5 | 0.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 1.1 | 1.0 | 1.2 | 0.9 | 1.0 |
Operating Income | -1.1 | -1.0 | -1.2 | -0.9 | -1.0 |
EBITDA | -1.1 | -1.0 | -1.2 | -0.9 | -1.0 |
Other Income / Expense | 0.0 | -0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.0 | -0.0 | 0.0 | 0.0 | 0.0 |
Income Before Income Taxes | -1.1 | -1.1 | -1.2 | -0.9 | -1.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -1.1 | -1.1 | -1.2 | -0.9 | -1.0 |
Consolidated Net Income / Loss | -1.1 | -1.1 | -1.2 | -0.9 | -1.0 |
Net Income Attributable to Common Shareholders | -1.1 | -1.1 | -1.2 | -1.0 | -1.2 |
Basic EPS | -$0.67 | -$0.63 | -$0.55 | -$0.43 | -$0.59 |
Diluted EPS | -$0.67 | -$0.63 | -$0.55 | -$0.43 | -$0.59 |
Basic Shares Outstanding | 1.6M | 1.7M | 2.2M | 2.3M | 1.9M |
Diluted Shares Outstanding | 1.6M | 1.7M | 2.2M | 2.3M | 1.9M |